Company Overview
Revelation Biosciences, Inc. operates as a clinical-stage life science company dedicated to the specific goal of rebalancing inflammation to optimize human health. The enterprise functions within the healthcare sector, specifically targeting the biotechnology industry where it develops proprietary formulations to address inflammatory conditions. The company's current market capitalization stands at $4.20M, while its annual revenue is not available for reporting, and the employee count is listed as N/A. The combination of a market cap of $4.20M and the absence of reported revenue figures indicates that the company is in a very early developmental stage, likely relying on external capital to fund clinical trials before generating significant commercial income.
Financial Health
The financial statements reveal a revenue of N/A, a net income of $-14,865,177, and an EBITDA of $-9,043,756, highlighting a substantial gap between revenue generation and profitability that points to high operational costs typical of clinical-stage biotechnology firms. The company's free cash flow is recorded at $-4,971,979, which signifies a heavy reliance on external financing rather than internal cash generation to sustain daily operations and research activities. All three margin metrics—gross margin at 0.0%, operating margin at 0.0%, and profit margin at 0.0%—indicate that the company has not yet achieved profitability on a percentage basis, reflecting the capital-intensive nature of bringing a product candidate like Gemini to market. The balance sheet shows a cash reserve of $10.76M against total debt of $746,784, suggesting a relatively strong liquidity position despite the negative earnings, though the debt-to-equity ratio of 8.43 implies significant leverage relative to shareholders' equity. The current ratio is reported at 5.41, indicating that the company holds a large amount of current assets relative to its current liabilities, which suggests robust short-term liquidity and a low risk of immediate insolvency. Furthermore, the return on equity is -131.4% and the return on assets is -62.3%, metrics that reveal that management has not yet generated positive returns on the capital invested, a common characteristic for companies in the clinical development phase.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -0.34, a figure that implies the market is pricing in future earnings growth that has not yet been realized by the company's current financial performance. The price-to-book ratio stands at 0.20, indicating that the stock is trading at a significant discount to its book value, which often occurs with biotechnology companies that hold substantial intangible assets or are in pre-revenue stages. Alternative valuation metrics such as the price-to-sales ratio of N/A and an EV/EBITDA of 0.64 suggest that traditional multiples are not applicable, yet the low EV/EBITDA relative to cash holdings provides a different perspective on enterprise value. The 52-week high is $44.77 and the 52-week low is $1.11, meaning the current trading price sits in a highly volatile range relative to the company's maximum valuation over the past year. The beta value is -0.13, which is an unusual negative coefficient that implies the stock's price moves inversely to the broader market or is decoupled from standard market volatility patterns, creating a unique risk profile for traders.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is also N/A, making it impossible to calculate growth rates from historical data, though the transition from N/A revenue growth to reported losses implies the company is shifting from discovery to development phases. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, as indicated by the N/A and 0.0% figures respectively, which confirms that all available capital is being reinvested into the development of lead product candidates rather than returned to shareholders. This reinvestment strategy is standard for clinical-stage biotechs that prioritize advancing their proprietary platforms over immediate income distribution. The overall growth and income profile is characterized by a lack of historical growth data and a complete absence of dividend income, reflecting a capital-intensive business model focused entirely on long-term asset development.